Abstract: Funding for biomedical research has shifted from government to the private sector. One reason is rapid expansion in the number and strength of U.S. biotechnology companies, which collectively spend more than $6 billion a year on biomedical research. Most of these companies are not yet profitable and therefore depend on flows of capital from private investors, Wall Street, and large pharmaceutical company collaborations. Investment in the new drugs, devices, and vaccines in this pipeline is sensitive to signals emanating from the debate on health care reform, suggesting that new federal policy will have a major impact on steering the type of innovation to emerge in the future.
H
ealth care reform has heightened interest in measures of medical innovation and raised the stakes for those involved in the business of creating and selling new products. Here we update a number of measures of innovation published in a previous DataWatch. 1 We also provide an overview of a uniquely American industry now playing a central role in health care innovation: more than 1,200 companies primarily engaged in biotechnology research and development.
Participants in this young industry are increasingly making their voices heard in the debate over health care reform; thus, it is important for policymakers to understand the factors that are driving innovation in this arena. We contrast the biotechnology industry with the traditional pharmaceutical companies and describe the sources of financing for biotechnology companies, what they have accomplished, and their work in progress.
National Investment In Research And Development
Recent figures from the National Science Foundation estimate that U.S. research and development (R&D) expenditures by all sponsors totaled $161 billion in 1993. 2 In constant dollars this is only a 1 percent increase since 1988. The federal government provides 43 percent of these funds but performs only 11 percent of the R&D work. Industry contributes 51 percent of the money and performs 70 percent of the R&D, with universities and other not-for-profit institutions making up the difference. 3 The National Institutes of Health (NIH) provides more finely grained estimates according to sources of funds and where this work is performed (Exhibit 1). Since our previous report in 1988, there has been a 50 percent increase in current-dollar health R&D spending to more than $30 billion. This represents a constant-dollar increase of only 22 percent, however. 4 The proportion of these expenditures borne by industry has continued to climb and is now believed to account for more than half of all health R&D in the United States. In addition to the $9.7 billion 1993 NIH appropriation, federal agencies committing more than $100 million per year to health-related R&D include several Public Health Service agencies (the Centers for Disease Control and Prevention, the Food and Drug Administration, and the Agency for Health Care Policy and Research), as well as the Departments of Agriculture, Defense, Energy, and Veterans Affairs and the National Aeronautics and Space Administration.
The distribution of effort among entities that perform federally sponsored health research has changed little from the mid-1980s, with roughly half of D ATAWATCH 2 17 the funds going to universities and the remainder divided between federal institutions and other entities. The universities' share of NIH dollars is slightly higher, about 60 percent. The number of persons in NIH-sponsored research training programs has been fairly level over the past decade, averaging between 12,000 and 13,000. 5 Since 1988 the large pharmaceutical companies have spent more on R&D than the annual NIH appropriation. The Pharmaceutical Manufacturers Association (PMA)-now the Pharmaceutical Research and Manufacturers of America (PhRMA)-reported that its members, "the researchbased pharmaceutical industry," spent $12.6 billion on R&D in 1993, up 13.5 percent from the previous year. 6 PhRMA expects this year's figure to be $13.8 billion, up only 9 percent-the first year of less than double-digit growth since 1977. 7 (About 82 percent of this total is spent in the United States.)
Despite the growth in R&D spending, the number of new drugs approved by the FDA each year has remained in a range of twenty to thirty for the past decade. The time required for FDA review has dropped 10-15 percent since the mid-1980s to an average of 26.5 months in 1993. 8 Of the twentyfive approvals last year, three were biotechnology products and one was a vaccine. These biologics enjoyed a shorter average review time of 19.8 months. The Prescription Drug User Fee Act of 1992 was intended to further accelerate approvals, by allowing the FDA to collect fees from applicants to support a 600-person increase in its professional staff.
The U.S. Biotechnology Industry
Since the founding of pioneering companies, such as Genentech in 1976, Biogen in 1978, and Centocor in 1979, a new U.S. industry has defined itself in terms of its R&D focus, the technology employed, and an extraordinary system of funding projects still years away from commercialization.
The accounting firm of Ernst and Young has tracked financial performance of biotechnology companies for several years and has compiled a series of reports on the industry. 9 These provide an overview for comparison with the large pharmaceutical companies. For the purposes of this analysis, a "universe" of biotechnology companies includes 1,272 companies, of which 235 are publicly held. These companies have a mean age of thirteen years and an average of seventy-six employees. There was a bulge in the pattern of company formation in the mid-1980s, but growth continues with more than 100 companies organized in the past two years.
Exhibit 2 presents aggregate financial data to contrast the fifteen largest pharmaceutical companies with the biotechnology universe for which Ernst and Young has assembled data. Global sales by United States-based biotech companies totaled $7 billion in 1992, compared with $114 billion for the large pharmaceutical companies, yet R&D expenditures were almost half of those of the big companies. This works out to $59,000 of R&D per employee in biotech companies, compared with $19,000 in large pharmaceutical companies. R&D expenses as a percentage of sales average more than 80 percent in the biotechnology industry, in contrast to PhRMA's estimate of just over 18 percent for 1994. A similar contrast is seen between large and small medical device companies: According to the Health Care Technology Institute, companies with less than $5 million in sales spent 77.5 percent of sales on R&D, while for those with more than $100 million in sales, the figure was 4.5 percent. 10 Spending by these small companies is not compatible with profitability in an industrial steady-state. It indicates that the current period is one of evolution in the organization and financing of biomedical research.
Although large pharmaceutical companies have been consistently profitable, individual companies experience major variations in their rate of sales and profit growth, according to the life cycle of major products. In contrast, all but a few biotechnology companies are incurring net losses, year after year, and are funding operations either through the sale of stock or via technology deals with the major pharmaceutical companies. According to investment analysts who follow the industry closely, approximately half of biotechnology companies have less than two years of cash reserve, even though many of these companies need to increase spending to move their products into clinical development.
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Exhibit 3 illustrates the range of products still in development at the largest biotechnology companies. Another survey of seventy-nine companies tabulated 745 publicly disclosed products, of which 250 are in human clinical trials for more than 365 medical indications.
12 Exhibit 4 shows the biotechnology products either approved in the United States or with applications pending at the FDA.
It is important to note that not all of the U.S. biotechnology R&D effort is taking place in young biotechnology companies. In a recent study of eight large pharmaceutical companies, it was determined that a third of their in-house research projects were based on modem molecular biology.
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Financing Biotechnology
Exhibit 5 shows selected financial highlights of biotechnology companies in different market segments. The money to start and sustain biotechnology research typically comes from different sources, depending on its stage of development. So-called seed financing is almost always provided by venture capitalists. Typically, the investment decision is made by the general partner of a limited partnership that represents the investment interests of several life insurance companies, pension funds, and university endowments. These venture capitalists are usually quite experienced in evaluating specific technologies and markets and often become involved in the management of new companies by serving on the board of directors. Seed financing ranges in size from a few hundred thousand to one or two million dollars.
As a fledgling company proves itself by assembling its technical and management team and achieves milestones in the research lab, it can raise additional capital. The next investment round may be from $2 million to $10 million, enough to last for one to two years as the company continues to expand its R&D effort. If the company is thought to be making good progress, investors will be willing to pay a higher price per share at each successive round. The ownership interest of early investors is diluted by the sale of new stock, but the value of their original holdings increases as long as the share price keeps going up. Recombinant Capital, a consulting firm that tracks investments in biotechnology, calculates that $723 million was raised by private companies in 1993; this amount is similar to that of the previous two years.
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importance to these deals as validation that the biotechnology company is on the right track and has technology of value. Biotech/ pharmaceutical company deals come in many varieties, but it is common to see large companies pay the full cost of research on specific biotechnology projects for which they will receive marketing rights. In addition to payment for work done, the smaller company earns cash payments as the product moves through preclinical and human trials, as well as royalties if there are eventual sales. As much as biotech investors like to see this corporate endorsement, they are also wary of companies that give away too much in the way of marketing rights. This is because the greatest slice of pharmaceutical profit margins historically is earned by the entity that controls manufacturing and marketing. Hoping to get the best of both worlds, biotechnology companies try to retain the right to make and sell the results of their innovative work for certain medical indications or in specified geographic territories or medical practice settings (hospital versus doctor's office). Ernst and Young estimates that payments from large pharmaceutical companies to U.S. biotechnology companies have recently been exceeding $2 billion per year, if both contract R&D and equity investments are considered.
Individual venture capital partnerships rarely contribute more than $5 million to a single company. At some point, typically after one to three private investment rounds, most biotechnology companies must access the public securities market. The Initial Public Offering (IPO) is a highly regulated process, after which a company assumes many new obligations to report financial and business results to its new shareholders and the public. Biotechnology IPOs typically have yielded $10 million to $25 million in capital, although a handful have been in the $100 million range. The IPO also represents a watershed for early investors, who will achieve some degree of "liquidity"-a mechanism for selling some or all of the shares acquired in the private rounds.
Once company's shares are publicly traded, the company can raise additional money in follow-on offerings if there is investor appetite for its shares. For biotechnology, this is a highly seasonal phenomenon, with periods of intense investment interspersed with months in which there is very little financing activity. The biotechnology financing "window" appears to be influenced by the overall economic environment as well as by industry-specific events.
It is widely believed in the industry that health care reform has slowed investment in biotechnology, because of the uncertainty that President Clinton's early proposals cast over the entire health care economy. More specifically, discussion of formal or informal price controls in the form of a breakthrough drug committee has been blamed for the loss in investor confidence because this form of oversight would reduce the financial upside for the most innovative (and risky) forms of R&D.
There has been a decline in money obtained from public markets, but publicly traded biotech companies have been resourceful in tapping a novel financing mechanism: going back to private investors who were willing to buy stock with restricted resale privileges at a 10-20 percent discount to the public common stock price. According to Alex. Brown and Sons, a Baltimore firm, the prices of many biotechnology stocks fell 30-40 percent in 1993, before recovering somewhat in the fourth quarter. 15 Some of this was undoubtedly due to disappointing news about some key biotechnology products in development, but large pharmaceutical stock prices also lost 10-20 percent of their value in 1993, suggesting that the market capitalization of the entire industry was negatively affected by the climate of health care reform.
Industry spokespersons argue that lower stock prices mean that the cost of capital is higher and that biotechnology companies therefore will scale back their growth, reducing R&D investment in important areas such as acquired immunodeficiency syndrome (AIDS) and cancer. These linkages between cost of capital and research effort are difficult to prove, but the logic is quite plausible given the industry's need for $25 billion in public risk capital over the next ten years. 16 This period of health reform comes at a critical time in the evolution of the biotechnology industry. As the industry matures toward a stage of greater self-sufficiency (funding R&D through sales), there will be an inevitable period of consolidation, with mergers, acquisitions, and even business failures.
From discussions with many industry leaders, we find that they clearly understand that high prices and generous reimbursement should not reward innovation for the sake of novelty alone. Their concern is that current reform proposals do not allow for clear economic signals that reward innovators on the basis of the value they bring, measured in terms of improved health outcomes and averted health care expenditures. Policy must be carefully considered so that the health care system does not give mediocre returns for high-risk projects that are successful in producing high-value products. 
